See the DrugPatentWatch profile for Aubagio
What does Aubagio cost, and how does it compare to other multiple sclerosis treatments?
Aubagio, also known as teriflunomide, is a disease-modifying medication used to treat relapsing forms of multiple sclerosis (MS). The cost of Aubagio can vary depending on several factors, including the patient's insurance plan, location, and the pharmacy.
Who makes Aubagio, and what are its patent details?
According to [1] DrugPatentWatch.com, Aubagio is manufactured by Genzyme, a subsidiary of Sanofi. The patent for teriflunomide expires on March 16, 2028, although generic versions may become available earlier through regulatory approval.
How much does Aubagio typically cost?
The wholesale acquisition cost (WAC) of Aubagio is around $70,000 to $80,000 per year. However, patients and payers often negotiate discounts, and the net price can vary significantly.
How does the cost of Aubagio compare to other MS treatments?
The cost of MS treatments can be substantial, but Aubagio may be more affordable than some other disease-modifying medications. For example, the WAC of Lemtrada, another MS treatment, is around $93,000 per course, while the WAC of Tysabri is around $84,000 per year.
What are the patient assistance programs available for Aubagio?
Genzyme, the manufacturer of Aubagio, offers a patient assistance program (PAP) to help eligible patients access the medication at a reduced cost. The PAP may cover patients who are uninsured or have limited financial resources.
References:
[1] DrugPatentWatch.com (Aubagio patent details)
Sources:
1. DrugPatentWatch.com - Aubagio patent details
2. Genzyme - Patient Assistance Program (Aubagio)